viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals gears up to pursue global growth strategy in 2021


The company is focused on its core business of executing its growth strategy and become a world-leading, vertically integrated, biopharma company focused on the development and production of phytocannabinoid derived medications for targeted global markets.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals gears up to pursue global growth strategy in 2021

Quick facts: MGC Pharmaceuticals Ltd


Price: 3.175 GBX

Market Cap: £75.72 m

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) plans to pursue its new growth strategy this year and is confident it will continue its trajectory of delivering strong commercial results.

Late last year, the company announced it would be the recipient of a 3.1 million Euro (~A$5 million) cash grant to set up a fully functional GMP certified facility in Malta to produce a COVID-19 anti-inflammatory product ArtemiC™ in liquid dose form.

The grant from Malta Enterprise will enable the company to renovate and extend its existing Clinical Research Organisation (CRO) facility in Malta.

This will create a European manufacturing hub for ArtemiC™ with the ability to scale production to meet expected growing demand following positive clinical trial results.

The European Union GMP-compliant facility will be able to produce 10,000 units of liquid dose medicines per day.

European manufacturing hub

The company has received strong support from the Maltese government through Malta Enterprise to establish the world-class GMP facility to respond to the growing pharma and cannabis industries on the island.

Construction of the extension to the MXC Malta facility has commenced and is expected to be completed in the second quarter of 2021.

Upon completion of the facility, MGC Pharma will be in a strong position to streamline global distribution via Malta’s convenient shipping access to the entire globe.

Initial target markets for the distribution of ArtemiC™ will be Israel, Russia, the CIS countries and countries in the Balkan region as determined by a distribution agreement signed with KS Kim International, a wholly-owned subsidiary of SK-Pharma group.

ArtemiC™ strong clinical trial results

In December, the company’s Phase II double-blind, placebo-controlled clinical trial for ArtemiC™ on those diagnosed with COVID-19 met all the Phase II primary and secondary endpoints and was demonstrated to improve the clinical recovery of the patients.

This Phase II trial involved 50 infected patients across three independent hospital sites in Israel and India, with 33 in the treatment group and 17 in the placebo group.

The full results have demonstrated to improve the health status of COVID-19 patients with none of the patients in the treatment group required additional oxygen, mechanical ventilation or admission to intensive care where all of these events were reported in the placebo group.

MGC Pharma is now in a strong position to respond to a significant potential increase in the demand for ArtemiC™ in the immediate future as a supplement, and in the future as part of a Phase III study.

Phase III clinical study planned in H1

Further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in the company’s EU GMP facilities, as IMP under a new brand name.

Different indications related to inflammation and cytokine storm will be considered as future development goals and include a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, flu and chemotherapy patients.

Regulatory approvals to commence the Phase III Clinical Trial will be progressed with the Brazilian medical authority (Anvisa), the EU Novel Food Authority and submissions are expected to be made in the first quarter of 2021.

The company plans to develop and commence a Phase III Clinical Trial in the first half of 2021.

Upon completion of a successful Phase III clinical trial, the company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.

Successful results of Phase III will lead for a pre-IND meeting with Food and Drug Administration (FDA, to initiate the registration process for ArtemiC™ as an IMP.

Supply agreements and production

On trial completion and the release of positive results, the production of ArtemiC™ will move to MGC Pharma’s GMP-certified production facility in Slovenia.

It expects to rapidly advance discussions on a commercial scale for ArtemiC™ supply agreements on publication of the positive data.

Additionally, MGC Pharma is exploring the wider uses of ArtemiC™ to encompass other conditions that cause cytokines storm.

UN reclassification implications

Notably, MGC Pharmaceuticals is well-positioned to benefit from the UN’s decision late last year to remove cannabis and its derivatives from schedule IV following recommendations from the World Health Organisation (WHO).

Cannabis and its derivatives will now be contained under Schedule I of the 1961 UN Single

This removal, alongside other recent legislative changes, further demonstrates the rapidly changing political perspectives on cannabis and the use of cannabis for medicinal purposes which will make operating in the sector less challenging, more efficient and more profitable.

The company believes this effectively validates the global medicinal phytocannabinoid market where MGC Pharma has been established and operating for a number of years.

This gives the company first-mover advantage and the company's flagship phytomedicines will have far fewer obstacles to overcome as they work towards market authorisation, registration and patient access.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 1 day ago

4 min read